AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial

Live updates

1. 1d ago

   AstraZeneca Partners with Summit Therapeutics for Datroway Evaluation

   AstraZeneca and Daiichi Sankyo are collaborating with Summit Therapeutics to evaluate a Datroway combination. This partnership follows a period of instability for AstraZeneca's oncology pipeline, including the Phase III SERENA-4 failure of the breast cancer drug Etcamah and a NICE rejection of Enhertu for advanced HER2-low breast cancer. The company is also testing AZD8205 in a Phase I/IIa study for patients with metastatic or advanced solid malignancies, either as a monotherapy or combined with other anti-cancer agents.

   Why it matters

   AstraZeneca is managing multiple clinical setbacks across oncology and rare diseases. Recent failures include the drug Ultomiris missing statistical significance for event-free survival in a late-stage trial for blood vessel complications. These combined results have raised concerns about the stability of the company's drug development pipeline.

   What is confirmed

   • AstraZeneca and Daiichi Sankyo are collaborating with Summit Therapeutics to evaluate a Datroway combination.
   • A Phase I/IIa study is evaluating AZD8205 for patients with advanced or metastatic solid malignancies alone or with anti-cancer agents.
   • The breast cancer drug Etcamah failed its Phase III SERENA-4 primary endpoint for progression-free survival.
   • NICE rejected Enhertu for advanced HER2-low breast cancer.
   • Ultomiris failed a late-stage trial for blood vessel complications following stem cell transplants.

   What to watch next

   • Clinical trial results for the Datroway combination
   • Phase I/IIa outcome data for AZD8205
   Sources used for this update (4)

   1. jen.jiji.com — Villa Pamphili Murders, Kaufmann's defense requests a new expert opinion: this time on mental capacity
   2. jen.jiji.com — Angelilli (Lazio): "Call for tenders of 4 million for blue economy"
   3. uk.finance.yahoo.com — AstraZeneca, Daiichi Sankyo to Evaluate Datroway Combo Across ...
   4. ctv.veeva.com — A Phase I/IIa Study of AZD8205 Given Alone or Combined, in ...
   confidence 100%
2. 3d ago

   AstraZeneca Faces Additional Setbacks in Breast Cancer and Rare Disease Pipeline

   AstraZeneca is experiencing a series of clinical and regulatory failures across its oncology and rare disease portfolios. The company's oral breast cancer drug Etcamah failed its Phase III SERENA-4 primary endpoint for progression-free survival. Additionally, NICE rejected Enhertu for advanced HER2-low breast cancer, a decision the company called devastating. In the rare disease sector, Ultomiris failed a late-stage trial for blood vessel complications following stem cell transplants, missing statistical significance for event-free survival at 26 weeks. These combined results have increased concerns regarding the drugmaker's overall pipeline stability.

   Why it matters

   The failures involve high-stakes treatments for advanced cancers and rare blood conditions. Etcamah had previously received accelerated FDA approval, making its Phase III failure particularly significant. The Ultomiris setback adds to a broader pattern of missed goals for the company in 2026.

   What is confirmed

   • Etcamah failed to meet its primary endpoint of progression-free survival in the Phase III SERENA-4 trial.
   • NICE rejected Enhertu for the treatment of advanced HER2-low breast cancer.
   • Ultomiris did not achieve statistical significance for event-free survival at 26 weeks in patients with haematopoietic stem cell transplant-associated thrombotic microangiopathy.

   What to watch next

   • Outcome of AstraZeneca discussions with global health authorities regarding the adult indication for Ultomiris
   • Further regulatory responses or appeals following the NICE rejection of Enhertu
   Sources used for this update (9)

   1. jen.jiji.com — Fuels, Gdf controls with Antitrust: prices and dispensed quantities verified on Italian network
   2. jen.jiji.com — Latvia votes with Russia's shadow, Premier Kulbergs aims for reconfirmation /Adnkronos
   3. www.distillintelligence.com — Latest AstraZeneca Australia News & Announcements
   4. pharmaphorum.com — Surprise Enhertu rejection follows NICE process change
   5. jen.jiji.com — Aurora Ramazzotti and Nikita Perotti in first place in the Dancing with the Stars ranking: what happened
   6. jen.jiji.com — Dancing with the Stars without Selvaggia Lucarelli, she breaks the silence: "It's all wonderful"
   7. talkwinchester.com — AstraZeneca’s rare disease drug misses main goal in late ...
   8. www.marketbeat.com — Astrazeneca (AZN) FDA Approvals, PDUFA Dates & Drug Alerts ...
   9. www.marketscreener.com — AstraZeneca PLC: Official Announcements - Stock Market News
   confidence 100%
3. 7d ago

   AstraZeneca's breast cancer drug Etcamah misses goal in late-stage trial

   AstraZeneca's oral breast cancer drug Etcamah, also known as camizestrant, did not meet its primary endpoint of progression-free survival in the Phase III SERENA-4 trial when combined with palbociclib in first-line advanced ER-positive, HER2-negative breast cancer. The trial showed only a numerical improvement. This marks a setback for the recently approved treatment, which received accelerated approval from the US FDA.

   Why it matters

   The SERENA-4 trial failure reinforces a tough first-line pattern for oral SERDs, with Roche's giredestrant also missing its first-line phase 3 trial. AstraZeneca's breast cancer drug development is under scrutiny, with investors advocating for diversification into new therapy areas for sustainable growth.

   What is confirmed

   • AstraZeneca's Phase III SERENA-4 trial evaluating Etcamah (camizestrant) in combination with palbociclib failed to meet its primary endpoint of progression-free survival.
   • The SERENA-4 trial showed only a numerical improvement in progression-free survival over anastrozole plus palbociclib.
   • AstraZeneca's Etcamah received accelerated approval from the US FDA for a defined group of patients.

   Still unconfirmed

   • The detailed results of the SERENA-4 trial have not yet been reported.

   What to watch next

   • AstraZeneca's future strategy for its breast cancer drug development
   • Investors' reaction to the SERENA-4 trial failure
   • Upcoming trial data and announcements from AstraZeneca
   Sources used for this update (15)

   1. jen.jiji.com — Pope Leo, today begins his apostolic journey to France: heart of secularism, Macron will not attend masses
   2. jen.jiji.com — UniMarconi, on September 26 'A Lesson in the Square' returns, a discussion in Italian cities
   3. jen.jiji.com — Follini: "From Conte to Vannacci, anti-system forces know what game is being played on geopolitics"
   4. www.nature.com — Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation | Signal Tra....
   5. finance.yahoo.com — AstraZeneca (AZN) is Expanding its Oncology Engine. Can New Growth Offset Legacy Pressure?
   6. www.talk.bio — Oral SERDs after SERENA-4: narrower bets, not the end of the ...
   7. www.insidermonkey.com — AstraZeneca (AZN): Can Precision Medicine Offset a Narrower ...
   8. economictimes.indiatimes.com — astrazeneca drug development: Latest News & Videos, Photos ...
   9. www.marketbeat.com — AZN News Today | Why did Astrazeneca stock go down today?
   10. thearabianpost.com — FDA clears AstraZeneca’s Etcamah for advanced breast cancer
   11. jen.jiji.com — Dubai-Tel Aviv flight, what we know about the Flydubai plane: in 29 seconds it lost 4,000 meters of altitude
   12. article.wn.com — AstraZeneca's breast cancer drug fails in late-stage trial
   confidence 85%
4. 13d ago

   No new data available for AstraZeneca breast cancer drug trials

   Current intelligence shows no updated results or confirmed reports regarding AstraZeneca's late-stage breast cancer drug trials. Previous reports established that the NHS cleared Enhertu for HER2-low metastatic breast cancer patients after a prior NICE rejection. Additionally, the FDA granted accelerated approval to the breast cancer pill Etcamah on September 5. No new corroborated evidence has emerged to support the claim that a late-stage trial missed its goal.

   Why it matters

   The company is expanding its oncology portfolio through strategic regulatory wins in the UK and US. These approvals depend on cost-effectiveness valuations and international pricing agreements.

   What to watch next

   • Official clinical trial data release from AstraZeneca
   • Regulatory filings regarding late-stage trial outcomes
   Sources used for this update (2)

   1. pharma.economictimes.indiatimes.com — Research & Development
   2. www.quiverquant.com — Quiver News
   confidence 100%
5. 15d ago

   NHS Approves AstraZeneca and Daiichi Sankyo Breast Cancer Drug Enhertu

   England's National Health Service cleared Enhertu, a breast cancer drug developed by AstraZeneca and Daiichi Sankyo, for use in patients with HER2-low metastatic breast cancer. This approval reverses a previous rejection by NICE, which had originally denied funding based on cost-effectiveness. The reversal follows a U.S.-UK agreement to align medicine prices and updates to how the agency values drugs. This adds a regulatory win for AstraZeneca's oncology portfolio following the September 5 accelerated FDA approval of its separate breast cancer pill, Etcamah.

   Why it matters

   AstraZeneca is managing a varied oncology pipeline with recent successes and failures. While Enhertu is now available in England, the company recently saw a Phase III failure for Etcamah in one trial setting despite its FDA approval. These developments highlight the volatile nature of drug pricing and regulatory hurdles in global markets.

   What is confirmed

   • The NHS cleared Enhertu for patients with HER2-low metastatic breast cancer.
   • Enhertu is developed by AstraZeneca and Daiichi Sankyo.
   • NICE previously rejected funding for Enhertu on cost-effectiveness grounds.
   • The FDA granted accelerated approval for the breast cancer pill camizestrant, marketed as Etcamah, on September 5, 2026.

   Still unconfirmed

   • The NHS approval followed changes to drug valuation methods and a U.S.-UK agreement to align medicine prices.

   What to watch next

   • Further Phase III trial results for camizestrant
   • Patient uptake rates for Enhertu within the NHS
   Sources used for this update (3)

   1. jen.jiji.com — Autumn Equinox 2026, when does it arrive? Summer's hours are numbered
   2. jen.jiji.com — William Shatner at 95 surprises everyone, the legendary Captain Kirk debuts in metal
   3. finance.yahoo.com — AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Approved for NHS Use in England
   confidence 90%
6. 18d ago

   FDA Grants Accelerated Approval to AstraZeneca Breast Cancer Drug Etcamah

   The FDA granted accelerated approval on September 5, 2026, for AstraZeneca's breast cancer pill camizestrant, marketed as Etcamah. The drug is approved for a genetically driven form of metastatic breast cancer when used with a CDK4/6 inhibitor. This regulatory win follows a conflicting April vote by an FDA advisory panel that concluded the drug lacked patient benefit. The approval arrives as the company manages a mixed oncology portfolio, including a recent Phase III failure for the same drug in a different trial setting.

   Why it matters

   Etcamah is an oral selective estrogen receptor degrader. Its development has been volatile, marked by both regulatory hurdles and a failed primary endpoint in the SERENA-4 trial. The drug's commercial success depends on its ability to overcome previous clinical setbacks and negative advisory panel sentiment.

   What is confirmed

   • The FDA granted accelerated approval to camizestrant, sold as Etcamah, on September 5, 2026.
   • Etcamah is approved for use alongside a CDK4/6 inhibitor for patients with a genetically driven form of metastatic breast cancer.
   • An FDA advisory panel voted in April that the drug lacked patient benefit.

   What to watch next

   • Market response to the accelerated approval versus the SERENA-4 trial failure
   • Further UK recommendations for AstraZeneca oncology drugs like Enhertu
   Sources used for this update (4)

   1. finance.yahoo.com — AstraZeneca's Enhertu Breast Cancer Drug Gets UK Recommendation
   2. finance.yahoo.com — AstraZeneca (AZN) Wins FDA Approval for its Breast Cancer Pill After Regulators Voiced Doubts
   3. finance.yahoo.com — Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?
   4. www.marketscreener.com — US weighs allowing most pharma licensing deals with China, sources say
   confidence 100%
7. 21d ago

   AstraZeneca Breast-Cancer Drug Misses Goal

   AstraZeneca PLC stated that its breast cancer pill Etcamah, also known as camizestrant, failed to meet the primary endpoint in the Phase III SERENA-4 trial. The trial tested the drug in combination with Pfizer's palbociclib as a first-line treatment for advanced ER-positive breast cancer. The stumble represents a significant setback for the pharmaceutical company's oncology pipeline. Market analysts suggest that missing this target could potentially reduce future sales projections by billions of dollars, adding to a history of setbacks for oral selective estrogen receptor degraders.

   Why it matters

   The Phase III SERENA-4 trial evaluated Etcamah combined with palbociclib in previously untreated patients with ER-positive, HER2-negative advanced breast cancer, recording only a numerical improvement rather than meeting its main goal. This outcome deals a blow to a drug considered a key growth opportunity within AstraZeneca's oncology portfolio. Oral selective estrogen receptor degraders have faced multiple setbacks across the pharmaceutical sector, complicating development paths for similar therapies.

   What is confirmed

   • AstraZeneca reported that its breast cancer pill Etcamah missed its primary endpoint in the Phase III SERENA-4 trial.
   • The trial evaluated Etcamah in combination with palbociclib as an upfront first-line treatment for advanced ER-positive, HER2-negative breast cancer.

   Still unconfirmed

   • The trial miss may trim billions of dollars from AstraZeneca sales.

   What to watch next

   • Further clinical data releases regarding the SERENA-4 trial
   • AstraZeneca corporate updates on the oncology pipeline and sales impact
   Sources used for this update (9)

   1. WSJ — AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial
   2. astrazeneca.com — Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer
   3. STAT — Breast cancer pill from AstraZeneca misses mark in pivotal trial
   4. Fierce Pharma — AstraZeneca’s Etcamah flunks first-line breast cancer trial, adding to oral SERDs’ failure record
   5. Bloomberg.com — Astra Breast Cancer Pill Miss May Trim Billions From Sales
   6. FirstWord Pharma — AstraZeneca's oral SERD stumbles in Phase III first-line breast cancer trial
   7. jen.jiji.com — Food, Anir Confindustria: "For large-scale catering, more certainty on contracts and rules"
   8. jen.jiji.com — Ukraine, FBI's warning: "Russia plans targeted assassinations in the US and Europe"
   9. finance.yahoo.com — AstraZeneca’s Oncology Engine Faces a Key Test After Camizestrant Miss
   confidence 100%